Clinical Trial Update: A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) [Phase 3]

View source ↗

Summary

Phase 3 trial comparing venetoclax plus rituximab vs bendamustine plus rituximab in relapsed/refractory chronic lymphocytic leukemia; results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Bendamustine (Bendamustine)
• Rituximab (rituximab)
• Venetoclax (venetoclax)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Chronic Lymphocytic Leukemia | Phase 3 | Status: COMPLETED | Results posted: 2018-10-01